Most tesamorelin coverage stops at visceral fat. But the most methodologically interesting dataset on this peptide isn't a body-composition scan — it's a liver study that put needles into people twice, a year apart. If you're researching what is tesamorelin actually proven to do, and whether tesamorelin research extends beyond the HIV population it was approved for, the liver trial is where the argument gets serious — and where it also stops.

Here's the short version: tesamorelin has one randomised trial with paired liver biopsies, 61 participants, all of them living with HIV, published in 2019. Seven years later, nobody has replicated it outside HIV. That gap is the story.

What is tesamorelin, and why would it touch the liver?

Tesamorelin is a stabilised analogue of growth hormone-releasing hormone (GHRH). It acts on the pituitary to increase endogenous, pulsatile growth hormone secretion, which in turn raises IGF-1 and promotes lipolysis — with a disproportionate effect on visceral adipose tissue rather than subcutaneous fat. You can read the full compound background on our tesamorelin profile.

The liver rationale follows from that mechanism. Visceral fat and hepatic steatosis travel together, and reduced GH secretion is itself associated with fatty liver. So the hypothesis was reasonable: push GH pulsatility back up, and liver fat should fall. What made the resulting trial unusual for a peptide is that its investigators tested it against histology, not just imaging.

The 61-person biopsy trial

Stanley and colleagues randomised 61 people with HIV and a hepatic fat fraction above 5% to tesamorelin 2 mg subcutaneously once daily or matched placebo for 12 months, published in The Lancet HIV in 2019. The primary endpoint was change in hepatic fat fraction measured by magnetic resonance spectroscopy. Baseline characteristics: mean age 53, 80% male, low alcohol intake, roughly a third with histological NASH at entry and about half with no fibrosis.

What it found

Liver fat fell 32% in the tesamorelin arm and rose 5% on placebo — a relative reduction of about 37% over 12 months. Thirty-five per cent of tesamorelin participants dropped below the 5% hepatic fat threshold that defines steatosis, versus 4% on placebo. On paired biopsies, fibrosis progression occurred in 10.5% of the tesamorelin group versus 37.5% of placebo.

Follow-on work from the same cohort — hepatic transcriptomic analysis published in JCI Insight in 2020 — reported shifts in pathways related to inflammation, tissue repair and hepatic stellate cell activation, which is mechanistically coherent with the fibrosis signal.

What it didn't show

Several things deserve stating plainly:

  • The primary endpoint was liver fat, not disease resolution. The trial was not powered for NASH resolution or fibrosis improvement as a primary outcome. The fibrosis finding is secondary.
  • The denominators are tiny. Only a subset had usable paired biopsies, and 10.5% versus 37.5% translates to single-digit event counts on each side. That is a hypothesis-generating result, not a settled one.
  • The transcriptomics are not replication. They come from the same 61 participants. Reanalysing one cohort three ways doesn't make it three studies.
  • Everyone had HIV. Every participant was on antiretroviral therapy, a population with a distinctive metabolic and hepatic phenotype.

Seven years on, tesamorelin research is still inside HIV

This is the part that should shape expectations. MASLD/MASH became one of the most heavily invested therapeutic areas of the 2020s, with biopsy-endpoint trials running at scale. Tesamorelin did not join that wave in a general-population study. Its regulatory footprint hasn't moved either: the FDA approval that came in 2010 for HIV-associated lipodystrophy is still the only indication, and the March 2025 approval of EGRIFTA WR (the F8 formulation, bioequivalent to the earlier presentation, with weekly rather than daily reconstitution and less than half the injection volume) was a convenience and administration change — not a new indication and not new efficacy data.

So when you see tesamorelin marketed as a "liver peptide," the honest description is: one positive, well-conducted, small trial in a specific population, unreplicated elsewhere, with no regulator anywhere having reviewed it for a liver indication.

What a 2026 meta-analysis adds — and doesn't

A meta-analysis of five randomised controlled trials published in Obesity Research and Clinical Practice in January 2026 pooled body composition and metabolic outcomes in HIV-associated lipodystrophy. It reported significant reductions in visceral adipose tissue (−27.71 cm²), trunk fat (−1.18 kg), waist circumference (−1.61 cm) and hepatic fat percentage (−4.28%), plus an increase in lean body mass (+1.42 kg). Subcutaneous fat and BMI did not shift significantly.

That's a useful consolidation of the visceral and hepatic fat signal — but note the inclusion criteria. Every pooled trial sits in HIV-associated lipodystrophy. Pooling five studies from one population increases precision; it does not increase generalisability. A meta-analysis cannot manufacture evidence for a population that was never enrolled.

Because the mechanism works by raising GH and IGF-1, trials in this compound have consistently tracked IGF-1 and glycaemic measures — a reminder that the safety questions here are pharmacologically specific, not generic.

Is tesamorelin legal in Australia? The regulatory position

Tesamorelin has never been entered on the Australian Register of Therapeutic Goods (ARTG). There is no TGA-approved tesamorelin product in Australia for HIV-associated lipodystrophy or for anything else — which means there is also no Australian product information, no PBS listing and no locally assessed indication.

The picture overseas is narrow too. The FDA has approved tesamorelin since 2010, for HIV-associated lipodystrophy only. In Europe, the marketing authorisation application was withdrawn before approval in 2012, so tesamorelin has never been EMA-approved.

For anyone in sport: the World Anti-Doping Agency prohibits GHRH analogues, and tesamorelin falls squarely inside that class — prohibited at all times, in and out of competition. That applies to any Australian athlete under a WADA-compliant code, regardless of a product's regulatory status.

None of this tells you anything about safety or suitability. It tells you that in Australia, tesamorelin sits outside the approved-medicines system entirely — a research compound, not a treatment option. We cover the regulatory status of other compounds across our peptides library.

What would actually move the evidence

Three things, in order of importance: a randomised trial in MASLD without HIV; a biopsy-endpoint study powered for fibrosis as a primary outcome; and independent replication by a group unconnected to the original Massachusetts General Hospital cohort. Until at least the first of those exists, the correct summary of tesamorelin and the liver is "promising, small, and confined to one population."

Want the next tesamorelin readout as it lands? Join our free updates list — evidence-first, no hype, no product recommendations.

FAQ

Does tesamorelin reduce liver fat?

In one randomised, placebo-controlled trial of 61 people with HIV and fatty liver, tesamorelin 2 mg daily reduced hepatic fat by about 37% relative to placebo over 12 months. That result has not been replicated in a non-HIV population, and no regulator has approved tesamorelin for any liver indication.

Is tesamorelin approved for NASH or MASLD?

No. Tesamorelin's only approval anywhere is the FDA's 2010 approval for HIV-associated lipodystrophy. The March 2025 EGRIFTA WR approval changed the formulation, not the indication. It has never been approved for NASH, MASH or MASLD.

Is tesamorelin legal in Australia?

Tesamorelin is not on the ARTG, so there is no TGA-approved tesamorelin product in Australia and no approved indication here. It is also prohibited in sport, because WADA bans GHRH analogues at all times.

What is the strongest evidence for tesamorelin?

The largest body of randomised evidence is in HIV-associated lipodystrophy, where a January 2026 meta-analysis of five trials found reductions in visceral fat, trunk fat, waist circumference and hepatic fat, and a gain in lean mass — with no significant change in BMI or subcutaneous fat.

Sources

This article is information, not medical advice. Tesamorelin is FDA-approved only for HIV-associated lipodystrophy, was never EMA-approved, and is not on the ARTG in Australia. retatrutide.net.au is independent, sells nothing, and recommends no supplier — speak to a qualified Australian health professional about your own situation.